• Most Popular
  • Most Shared

Glaxo says cervical cancer vaccine works for longer

LONDON
Wed May 14, 2008 4:19am EDT

LONDON (Reuters) - GlaxoSmithKline said on Wednesday new data showed its Cervarix vaccine generated sustained, high levels of neutralizing antibodies against the two most common cervical cancer-causing virus types for 6.4 years.

Health  |  Stocks

Glaxo said on Wednesday the data, from an extended follow-up study, showed the longest duration of sustained neutralizing antibody levels reported against both virus types HPV 16 and 18 with a cervical cancer vaccine to date.

Experts believe that neutralizing antibodies -- so-called because they have the ability to neutralize cancer-causing virus types and prevent them from infecting cells in the cervix -- are essential for cervical cancer protection.

(Reporting by Mark Potter, Editing by Dan Lalor)
Health
Stocks


More from Reuters

Photo

Rajaratnam pleads innocent in Galleon case

NEW YORK (Reuters) - Galleon hedge fund founder Raj Rajaratnam and co-defendant Danielle Chiesi pleaded innocent on Monday to charges of securities fraud in what U.S. prosecutors describe as the biggest hedge fund insider trading case ever.

» More Top News
Demonstrators protest against the healthcare bill outside the Capitol in Washington December 15, 2009. REUTERS/Kevin Lamarque

Health bill passes crucial test

A sweeping U.S. healthcare reform bill appears headed for passage in the Senate after surviving a middle-of-the-night test vote.  Full Article | Video 

Healthcare Reform
Two men shake hands in a file photo. REUTERS/File

Let's make a deal

The battered M&A sector will make a tepid recovery in the coming year and three hot sectors will lead the way, according to a Thomson Reuters analysis.  Full Article 

Global Deals Review